No previous studies reported the efficacy of inhibiting UGCG in reducing leukemic CLL cell viability, which could be attributed to the utilization of less specific UGCG inhibitors, such as imino sugars-based molecules [6, 14, 20] and inadequate alteration in intracellular GluCer levels [6]. This evidence concerns the gene UGCG and B-cell chronic lymphocytic leukemia.